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Abstract
Introduction: A combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor 
blockers has been used to control proteinuria, following initial demonstration of its efficacy. However, recently 
concerns about the safety of this therapy have emerged, prompting several authors to urge for caution in its use. In the 
following case report, we describe the occurrence of a serious and unexpected adverse drug reaction after 
administration of a combination of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers to a 
patient with nephrotic syndrome and liver cirrhosis with severe portal hypertension.
Case presentation: We administered this combination therapy to a 40-year-old Caucasian man with liver cirrhosis in 
our Hepatology Clinic, given the concomitant presence of glomerulopathy associated with severe proteinuria. While 
the administration of one single drug appeared to be well-tolerated, our patient developed severe acute 
encephalopathy after the addition of the second one. Discontinuation of the therapy led to the disappearance of the 
side-effect. A tentative rechallenge with the same drug combination led to a second episode of acute severe 
encephalopathy.
Conclusion: We speculate that this adverse reaction may be directly related to the effect of angiotensin II on the 
excretion of blood ammonia. Therefore, we suggest that patients with liver cirrhosis and portal hypertension are at risk 
of developing clinically relevant encephalopathy when angiotensin-converting enzyme inhibitor and angiotensin II 
receptor blocker combination therapy is administered, thus indicating the need for a careful clinical follow-up. In 
addition, the incidence of this serious side-effect should be rigorously evaluated in all patients with liver cirrhosis 
administered with this common treatment combination.
Introduction
A combination therapy of angiotensin-converting
enzyme inhibitors (ACEIs) and angiotensin II receptor
blockers (ARBs) has been used to control proteinuria fol-
lowing initial demonstration of its efficacy [1]. However,
recent concerns about the safety of this therapy have
emerged, prompting several authors to urge for caution
in its use [2]. In this case report, we describe the occur-
rence of a serious and unexpected adverse drug reaction
after administration of the ACEI and ARB combination
therapy to a patient with nephrotic syndrome and liver
cirrhosis with severe portal hypertension. We suggest
that the described adverse reaction is most likely related
to the renal effects of the combination therapy and this
should be taken into account in high-risk patients pre-
senting with selected co-morbidities.
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A 40-year-old Caucasian man with liver cirrhosis and
nephrotic syndrome, presented to our Liver Unit in
December 2007. His liver disease had been diagnosed
when he was 14 years old. Viral and autoimmune etiolo-
gies as well as inborn errors of metabolism were then
excluded. After the occurrence of an episode of variceal
bleeding at the age of 28, a successful prophylaxis of
rebleeding with propranolol was started. From histological
examinations, he had been diagnosed with hepatoportal
sclerosis at age 30 and membranous glomerulonephritis
at age 33 requiring the administration of furosemide (125
mg/day).
In January 2008, he was admitted as an inpatient to our
Unit for a full evaluation for potential liver transplanta-
tion. He was asymptomatic and a physical examination
revealed a slight hepatomegaly and splenomegaly, with-
out asterixis, jaundice or ascites. An ultrasonography of
our patient demonstrated evidence of portal hyperten-
sion, including an enlarged portal vein diameter and the
presence of collateral circles. His proteinuria was 3.7 g/24
hours, despite the administration of losartan 50 mg/day
prescribed six weeks previously, with normal creatinine
values. Thus, ramipril 2.5 mg/day was added.
About 12 hours after the first dose of ramipril, our
patient became unconscious. His Glasgow Coma Scale
(GCS) was 6 (O1, V1, M4), blood pressure (BP) 130/80
and heart rate (HR) 60 bpm. No substantial changes from
baseline were observed in biochemistry and blood gas
analysis (Table 1); while his toxicological screening was
negative. A cerebral computed tomography (CT) scan
revealed no signs of compression or bleeding, while an
electroencephalogram (EEG) showed overall slow brain
activity compatible with toxic or metabolic alterations.
His oral therapy was withdrawn and treatment with
lactulose enema and intravenous hydration with
branched-chain amino-acids was started, leading to
recovery within 30-36 hours. After return to full con-
sciousness, angiotensin block was re-introduced and after
48 hours his encephalopathy symptoms relapsed (GCS =
6). His CT scan was again negative and his EEG was simi-
lar to the previous one; while his blood ammonia concen-
tration was dramatically elevated to 990 μg/dL. Our
patient was admitted to the intensive care unit (ICU),
where the episode was successfully treated.
Angiotensin block was re-introduced for a third time
with an addition of maximal lactulose therapy (oral and
by enema) and oral rifaximin. By then, our patient was
awake and conscious, although imperceptive and
detached from his environment. After four days, ACEIs
and ARBs were withdrawn, leading to a complete neuro-
logical recovery. He was discharged and remained
asymptomatic with no further episodes of hepatic
encephalopathy with low (normal) ammonia levels at
repeated checks for 10 weeks.
Discussion and conclusion
Targeting the renin-angiotensin system for BP control
was introduced in the 1980s by the approval of the two
main classes of drugs: ACEIs which are agents that hinder
the conversion of angiotensin I (ATI) to the vasoactive
angiotensin II (ATII), and ARBs which inhibit the ATI
receptor involved in vasoconstriction, aldosterone secre-
tion and sodium reabsorption. Both agents demonstrated
similar efficacy profiles, leading to recent debates over
the selection of initial antihypertensive medications [3].
Several clinical trials on humans were designed to
investigate the effects of these agents, alone or in combi-
nation, in the control of hypertension [4,5], heart failure
[6,7] and proteinuric kidney disease [2]. Most results con-
firmed that the ACEI and ARB combination therapy
induced a slight improvement in hypertension control [4]
and a definite reduction of proteinuria if concomitant
renal damage was present [8,9]. However, increased inci-
dences of hypotensive episodes [6,7], moderate to severe
hyperkalemia [7] and adverse renal outcomes [2], the lat-
ter primarily reported in patients without proteinuria;
have led to a reconsideration of the balance between the
risks (increases of serum creatinine) and benefits (reduc-
tions of proteinuria) of the ACEI and ARB combination
therapy. Renal side-effects, such as hyperkalemia and
excessive reduction of the glomerular filtration rate, as
well as potentially worse complications, such as acute
renal failure, have to be further and more systematically
evaluated. Thus, caution is advisable in the administra-
tion of this combination therapy until results from several
ongoing trials with specific renal endpoints (Design of
combination angiotensin receptor blocker and angio-
tensin-converting enzyme inhibitor for treatment of dia-
betic nephropathy (VA NEPHRON-D), Approaches to
testing new treatments in autosomal dominant polycystic
kidney disease: insights from the CRISP and HALT-PKD
studies, and Protocol of the Long-term Impact of RAS
Inhibition on Cardiorenal Outcomes (LIRICO) random-
ized trial)are available.
To the best of our knowledge, this is the first descrip-
tion of a serious, life-threatening adverse effect of the
ACEI and ARB combination therapy, possibly connected
to liver dysfunction in a patient with portal hypertension.
We infer that the unfavorable reaction could be directly
related to the effect of ATII on the excretion of blood
ammonia, although the contribution of co-morbidity and
multiple drug therapy cannot be ruled out.
As previously described in animal models [10], ATII is
essential to the control of ammonia production and
excretion by the proximal tubule. Although the effects on
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renin-angiotensin system in humans are still undefined,
our case suggests an overall reduction of renal excretion
through the kidneys. In turn, this could have accounted
for the abrupt rise in ammonia levels detected in a patient
with increased susceptibility due to the concomitant liver
cirrhosis and severe portal hypertension (Figure 1). We
suggest a careful clinical follow-up and, possibly, moni-
toring of blood ammonia concentrations when ACEI and
ARB combination therapy is administered to patients
with liver cirrhosis and portal hypertension. The inci-
dence of this serious side-effect associated with a com-
Table 1: Blood exams and gas analysis upon admission and during the two episodes of encephalopathy
Presentation After 1st adverseevent After 2nd adverse event Normal range
AST (U/L) 112 115 137 5-41
ALT (U/L) 71 81 84 7-41
Bilirubin (mg/dL) 1.7 2.8 2.7 <1
Creatinine (mg/dL) 0.8 0.9 0.8 0.7-1.3
Urea (mg/dL) 46 55 50 10-50
Albumin (g/dL) 1.5 1.6 1.6 3.6-4.8
Haemoglobin (g/dL) 9.4 11 10 13-17
WBC (103/μL) 3.9 4.9 5.0 4.0-10.0
Platelets (103/μL) 61 73 78 150.0-450.0
CRP (mg/L) 15 11 12 <5
PT (INR) 1.2 1.2 1.2 0.8-1.2
Na+ (mEq/L) 139 139 140 135-145
K+ (mEq/L) 4.7 5.0 4.2 3.6-5.2
pH 7.43 7.43 7.50 7.35-7.45
HCO3 (mmol/L) 23.6 22.1 24.6 21-23
AST: aspartate aminotransferase; ALT: alanine aminotransferase; WBC: white blood cell; PT: prothrombin time; INR: international normalized 
ratio; Na+: sodium, K+: potassium, HCO3: bicarbonate.
Figure 1 In healthy controls the excretion of ammonia is mediated by two mechanisms: liver detoxification and renal excretion. Renal excre-
tion is modulated by angiotensin II (ATII) at the level of the proximal tubule. In our patient the hepatic mechanism is impaired, due to the liver 
cirrhosis, making the renal route essential for elimination of ammonia. Suppression of ATII activity through a combination of angiotensin-converting 
enzyme inhibitors and angiotensin II receptor blockers prevented adequate renal excretion, leading to an abrupt rise in serum ammonia concentration 
and the described neurological complications.
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high-risk patients.
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